Thrombocytopenia

Am Fam Physician. 2012 Mar 15;85(6):612-622.

  Patient information: See related handout on low platelet count, written by the authors of this article.

Thrombocytopenia is defined as a platelet count of less than 150 × 103 per μL. It is often discovered incidentally when obtaining a complete blood count during an office visit. The etiology usually is not obvious, and additional investigation is required. Patients with platelet counts greater than 50 × 103 per μL rarely have symptoms. A platelet count from 30 to 50 × 103 per μL rarely manifests as purpura. A count from 10 to 30 × 103 per μL may cause bleeding with minimal trauma. A platelet count less than 5 × 103 per μL may cause spontaneous bleeding and constitutes a hematologic emergency. Patients who present with thrombocytopenia as part of a multisystem disorder usually are ill and require urgent evaluation and treatment. These patients most likely have an acute infection, heparin-induced thrombocytopenia, liver disease, thrombotic thrombocytopenic purpura/hemolytic uremic syndrome, disseminated intravascular coagulation, or a hematologic disorder. During pregnancy, preeclampsia and the HELLP (hemolysis, elevated liver enzymes, and low platelet count) syndrome are associated with thrombocytopenia. Patients with isolated thrombocytopenia commonly have drug-induced thrombocytopenia, immune thrombocytopenic purpura, pseudothrombocytopenia, or if pregnant, gestational thrombocytopenia. A history, physical examination, and laboratory studies can differentiate patients who require immediate intervention from those who can be treated in the outpatient setting. Treatment is based on the etiology and, in some cases, treating the secondary cause results in normalization of platelet counts. Consultation with a hematologist should be considered if patients require hospitalization, if there is evidence of systemic disease, or if thrombocytopenia worsens despite initial treatment.

Family physicians often see patients who present with a low platelet count. Although further inquiry may elicit additional signs and symptoms of systemic disease, the etiology of thrombocytopenia usually is not immediately apparent. A low platelet count may be the only hematologic abnormality. In adults, thrombocytopenia is a platelet count less than 150 × 103 per μL (150 × 109 per L). Cases are considered mild if counts are between 70 and 150 × 103 per μL (70 to 150 × 109 per L) and severe if less than 20 × 103 per μL (20 × 109 per L).1 Patients with a platelet count greater than 50 × 103 per μL (50 × 109 per L) often are asymptomatic. Patients with a count from 30 to 50 × 103 per μL (30 to 50 × 109 per L) rarely present with purpura, although they may have excessive bleeding with trauma. However, counts from 10 to 30 × 103 per μL (10 to 30 × 109 per L) may cause bleeding with minimal trauma, and counts less than 10 × 103 per μL increase the risk of spontaneous bleeding, petechiae, and bruising. Spontaneous bleeding (i.e., mucosal, intracranial, gastrointestinal, and genitourinary bleeding) is more likely in patients with platelet counts less than 5 × 103 per μL (5 × 109 per L), and is considered a hematologic emergency.2

SORT: KEY RECOMMENDATION FOR PRACTICE

Clinical recommendation Evidence rating References Comments

Corticosteroids are first-line treatment for immune thrombocytopenic purpura.

C

2, 21

Treatment is rarely indicated in patients with platelet counts greater than 50 × 103 per μL (50 × 109 per L).

Patients older than 60 years with thrombocytopenia should be evaluated for myelodysplastic syndrome or lymphoproliferative disorders.

C

2, 21

Patients with myelodysplastic syndrome usually will present with anemia and lymphoma with lymphadenopathy.

Pregnant patients with platelet counts greater than 115 × 103 per μL (115 × 109 per L) and no evidence of preeclampsia or HELLP (hemolysis, elevated liver enzymes, and low platelet count) syndrome do not require further evaluation.

C

9, 37

Gestational thrombocytopenia is common and does not pose a risk to the fetus or mother.

Patients with mild thrombocytopenia (i.e., platelet counts of 100 to 150 × 103 per μL [100 to 150 × 109 per L]) who are asymptomatic should have a platelet count repeated in two to four weeks.

C

16

Any change in clinical health or evidence of bleeding before repeat testing should prompt immediate reevaluation.

Patients with stable thrombocytopenia (platelet counts greater than 50 × 103 per μL) generally do not require activity restrictions and are able to tolerate most invasive procedures.

C

39, 41, 42

The information is based on long-term outcomes from patients with chronic immune thrombocytopenic purpura.


A = consistent, good-quality patient-oriented evidence; B = inconsistent or limited-quality patient-oriented evidence; C = consensus, disease-oriented evidence, usual practice, expert opinion, or case series. For information about the SORT evidence rating system, go to http://www.aafp.org/afpsort.xml.

SORT: KEY RECOMMENDATION FOR PRACTICE

View Table

SORT: KEY RECOMMENDATION FOR PRACTICE

Clinical recommendation Evidence rating References Comments

Corticosteroids are first-line treatment for immune thrombocytopenic purpura.

C

2, 21

Treatment is rarely indicated in patients with platelet counts greater than 50 × 103 per μL (50 × 109 per L).

Patients older than 60 years with thrombocytopenia should be evaluated for myelodysplastic syndrome or lymphoproliferative disorders.

C

2, 21

Patients with myelodysplastic syndrome usually will present with anemia and lymphoma with lymphadenopathy.

Pregnant patients with platelet counts greater than 115 × 103 per μL (115 × 109 per L) and no evidence of preeclampsia or HELLP (hemolysis, elevated liver enzymes, and low platelet count) syndrome do not require further evaluation.

C

9, 37

Gestational thrombocytopenia is common and does not pose a risk to the fetus or mother.

Patients with mild thrombocytopenia (i.e., platelet counts of 100 to 150 × 103 per μL [100 to 150 × 109 per L]) who are asymptomatic should have a platelet count repeated in two to four weeks.

C

16

Any change in clinical health or evidence of bleeding before repeat testing should prompt immediate reevaluation.

Patients with stable thrombocytopenia (platelet counts greater than 50 × 103 per μL) generally do not require activity restrictions and are able to tolerate most invasive procedures.

C

39, 41, 42

The information is based on long-term outcomes from patients with chronic immune thrombocytopenic purpura.


A = consistent, good-quality patient-oriented evidence; B = inconsistent or limited-quality patient-oriented evidence; C = consensus, disease-oriented evidence, usual practice, expert opinion, or case series. For information about the SORT evidence rating system, go to http://www.aafp.org/afpsort.xml.

Initial Evaluation

Thrombocytopenia can result from decreased platelet production, increased platelet consumption, or sequestration (Table 136). Common etiologies with clinical findings and suggested treatment are listed in Table 2,714  and clinical considerations to aid in diagnosis are listed in Table 3. A systematic approach should be used to evaluate incidental thrombocytopenia. During the patient history, physicians should inquire about easy bruising or petechiae, melena, rashes, fevers, and bleeding. They also should inquire about medication use, immunizations, recent travel, transfusion history, family history, and medical history. A history of acute and chronic alcohol use should be obtained. Any recent hospitalization or heparin exposure should raise the possibility of heparin-induced thrombocytopenia. Pregnant patients with visual symptoms, headaches, abdominal pain, or influenza-like symptoms may have preeclampsia or HELLP (hemolysis, elevated liver enzymes, and low platelet count) syndrome.

Table 1.

Etiologies of Thrombocytopenia

Decreased platelet production

Bone marrow failure (e.g., aplastic anemia, paroxysmal nocturnal hemoglobinuria, Shwachman-Diamond syndrome)

Bone marrow suppression (e.g., from medication, chemotherapy, or irradiation)

Chronic alcohol abuse*

Congenital macrothrombocytopenias (e.g., Alport syndrome, Bernard-Soulier syndrome, Fanconi anemia, platelet-type or pseudo–von Willebrand disease, Wiskott-Aldrich syndrome)

Infection† (e.g., cytomegalovirus, Epstein-Barr virus, hepatitis C virus, HIV, mumps, parvovirus B19, rickettsia, rubella, varicella-zoster virus)

Myelodysplastic syndrome

Neoplastic marrow infiltration

Nutritional deficiencies (vitamin B12 and folate)

Increased platelet consumption

Alloimmune destruction (e.g., posttransfusion, neonatal, posttransplantation)

Autoimmune syndromes (e.g., antiphospholipid syndrome, systemic lupus erythematosus, sarcoidosis)

Disseminated intravascular coagulation*/severe sepsis*

Drug-induced thrombocytopenia

Heparin-induced thrombocytopenia

Immune thrombocytopenic purpura*

Infection † (e.g., cytomegalovirus, Epstein-Barr virus, hepatitis C virus, HIV, mumps, parvovirus B19, rickettsia, rubella, varicella-zoster virus)

Mechanical destruction (e.g., aortic valve, mechanical valve, extracorporeal bypass)

Preeclampsia/HELLP syndrome

Thrombotic thrombocytopenic purpura/hemolytic uremic syndrome

Sequestration/other

Chronic alcohol abuse*

Dilutional thrombocytopenia (e.g., hemorrhage, excessive crystalloid infusion)

Gestational thrombocytopenia

Hypersplenism (e.g., distributional thrombocytopenia)

Liver disease (e.g., cirrhosis, fibrosis, portal hypertension)

Pseudothrombocytopenia

Pulmonary emboli

Pulmonary hypertension


HELLP = hemolysis, elevated liver enzymes, and low platelet count; HIV = human immunodeficiency virus.

*—More than one mechanism of action.

†—Thrombocytopenia with infection is usually caused by bone marrow suppression. In some cases, the thrombocytopenia is also immune-mediated.

Information from references 3 through 6.

Table 1.   Etiologies of Thrombocytopenia

View Table

Table 1.

Etiologies of Thrombocytopenia

Decreased platelet production

Bone marrow failure (e.g., aplastic anemia, paroxysmal nocturnal hemoglobinuria, Shwachman-Diamond syndrome)

Bone marrow suppression (e.g., from medication, chemotherapy, or irradiation)

Chronic alcohol abuse*

Congenital macrothrombocytopenias (e.g., Alport syndrome, Bernard-Soulier syndrome, Fanconi anemia, platelet-type or pseudo–von Willebrand disease, Wiskott-Aldrich syndrome)

Infection† (e.g., cytomegalovirus, Epstein-Barr virus, hepatitis C virus, HIV, mumps, parvovirus B19, rickettsia, rubella, varicella-zoster virus)

Myelodysplastic syndrome

Neoplastic marrow infiltration

Nutritional deficiencies (vitamin B12 and folate)

Increased platelet consumption

Alloimmune destruction (e.g., posttransfusion, neonatal, posttransplantation)

Autoimmune syndromes (e.g., antiphospholipid syndrome, systemic lupus erythematosus, sarcoidosis)

Disseminated intravascular coagulation*/severe sepsis*

Drug-induced thrombocytopenia

Heparin-induced thrombocytopenia

Immune thrombocytopenic purpura*

Infection † (e.g., cytomegalovirus, Epstein-Barr virus, hepatitis C virus, HIV, mumps, parvovirus B19, rickettsia, rubella, varicella-zoster virus)

Mechanical destruction (e.g., aortic valve, mechanical valve, extracorporeal bypass)

Preeclampsia/HELLP syndrome

Thrombotic thrombocytopenic purpura/hemolytic uremic syndrome

Sequestration/other

Chronic alcohol abuse*

Dilutional thrombocytopenia (e.g., hemorrhage, excessive crystalloid infusion)

Gestational thrombocytopenia

Hypersplenism (e.g., distributional thrombocytopenia)

Liver disease (e.g., cirrhosis, fibrosis, portal hypertension)

Pseudothrombocytopenia

Pulmonary emboli

Pulmonary hypertension


HELLP = hemolysis, elevated liver enzymes, and low platelet count; HIV = human immunodeficiency virus.

*—More than one mechanism of action.

†—Thrombocytopenia with infection is usually caused by bone marrow suppression. In some cases, the thrombocytopenia is also immune-mediated.

Information from references 3 through 6.

Table 2.

Common Etiologies of Thrombocytopenia with Clinical Findings and Suggested Treatment

Etiology Severity Clinical presentation Evaluation Treatment Comments

Bone marrow suppression by irradiation, chemotherapy, or neoplasia

Moderate to severe

History of exposure, comorbid preexisting disease, or malignancy

Acute leukemias present with fatigue, weakness, bruising, hepatosplenomegaly

Directed by preexisting diagnosis, specific cancer markers

Abnormal blood smear or bone marrow biopsy

Based on underlying etiology

Usually affects all cell lines

Chronic alcohol abuse

Mild to moderate

Findings range from normal to evidence of cirrhosis or hepatic failure

Positive screening questionnaire, abnormal liver function tests (AST/ALT > 2, GGT), macrocytosis, folate deficiency, hepatic imaging as clinically indicated

Cessation of alcohol use, vitamin and nutritional replacement

Cessation of alcohol use may lead to platelet rebound (> 500 × 103 per μL [500 × 109 per L]) at one to two weeks

Chronic liver disease

Mild to severe

Symptoms are variable based on evidence of cirrhosis, liver dysfunction, gastrointestinal bleeding, ascites, hepatomegaly, and jaundice

Abnormal intrinsic liver function testing, imaging and liver biopsy as clinically indicated

Based on etiology; often supportive

Hypersplenism often is present contributing to thrombocytopenia

Congenital thrombocytopenia

Mild to moderate

Long history of abnormal platelet count or family history of thrombocytopenia

Many disorders associated with giant platelets, neutrophil inclusions, or other congenital anomalies

Varies depending on primary abnormality

Often asymptomatic when there is no bleeding diathesis

Disseminated intravascular coagulation

Severe

Acute illness; bleeding, acute renal failure, hepatic and respiratory dysfunction, and shock are common clinical manifestations

Secondary to other comorbid conditions, such as sepsis, trauma, burns, or malignancy

\

Prolonged coagulation activation, elevated fibrin markers, and accelerated fibrinolysis (low fibrinogen levels)

Supportive treatment with platelet and clotting factor replacement therapy

Mortality rates exceed 20 percent; prognosis is based on treating the underlying disorder

Drug-induced thrombocytopenia

Moderate to severe

Can range from asymptomatic to evidence of clinical bleeding

Detailed history of recent prescription medications, nutritional supplements, and over-the-counter agents

Removal of offending agent

Serial platelet monitoring until normalization

May be initially indistinguishable from ITP

Often resolves within seven to 14 days after agent is discontinued

Gestational thrombocytopenia

Mild

Asymptomatic with platelet counts rarely < 70 × 103 per μL (70 × 109 per L)

Identified during initial prenatal CBC

No associated fetal thrombocytopenia

Spontaneous resolution after delivery

No treatment indicated

Platelet counts approaching 50 ×103 per μL (50 × 109 per L) often are considered ITP and treated with corticosteroids or IVIG

Possible immunologic etiology

May be difficult to distinguish from ITP before delivery

Up to 15 percent of infants with thrombocytopenia are born to women with ITP

Heparin-induced thrombocytopenia

Mild to moderate

Thrombocytopenia or a 50 percent reduction after exposure to heparin or low-molecular-weight heparin

Arterial and venous thrombosis

History of heparin use; erythema or necrosis at site of injection; thrombosis; ELISA test for presence of platelet factor 4 antibodies

Immediate withdrawal of heparin; treatment with nonheparin anticoagulant

Warfarin (Coumadin) monotherapy may induce thrombosis and is contraindicated in the acute setting

Immune thrombocytopenic purpura

Moderate to severe

Often asymptomatic, although symptoms can range from petechiae and easy bruising to severe bleeding diathesis (rare)

Secondary ITP may present in patients with autoimmune disorders, infections (e.g., cytomegalovirus, Epstein-Barr virus, Helicobacter pylori, hepatitis C virus, human immunodeficiency virus, varicella-zoster virus), and lymphoproliferative disorders

Remainder of CBC normal; normal peripheral blood smear; absence of clinically associated conditions

Secondary ITP causes should be investigated as clinically indicated

Corticosteroids, IVIG, rituximab (Rituxan), splenectomy

Treatment not indicated for platelet counts > 50 × 103 per μL unless active bleeding

Secondary ITP also requires treatment of underlying cause

Diagnosis of exclusion

Patients older than 60 years should have bone marrow biopsy to rule out myelodysplastic syndrome or lymphoproliferative disorder

MMR vaccination causes one case of ITP per 40,000 doses

Infections (viral or rickettsial)

Mild to moderate

Viral: prodrome or asymptomatic; known viruses include cytomegalovirus, Epstein- Barr virus, hepatitis B and C viruses, human immunodeficiency virus, parvovirus B19, varicella-zoster virus

Rickettsial: Lyme disease, Rocky Mountain spotted fever, ehrlichiosis; tick-borne illnesses present with fever, headache, malaise, arthralgias, and rash

Viral: diagnosis based on viral etiology; directed antiviral titer testing if available

Rickettsial: ELISA testing may be useful

Viral: based on viral etiology; most self-limited viral infections are supportive

Rickettsial: doxycycline is recommended in symptomatic tick-borne disease

Viral: varicella (live) and influenza A (H1N1) vaccinations have been reported to cause mild transient thrombocytopenia

Rickettsial: ehrlichiosis causes more severe thrombocytopenia than Rocky Mountain spotted fever and Lyme disease

Preeclampsia/HELLP syndrome

Mild to moderate

Elevated blood pressure, visual symptoms, headache, right upper quadrant abdominal pain, influenza-like symptoms

CBC, liver function test, urine protein level, increased uric acid level, increased LDH level, basic metabolic panel

Delivering the fetus; intravenous magnesium sulfate

Recovery usually is within three days of delivery

If persistent beyond the third day after delivery, presume thrombotic thrombocytopenic purpura

Pseudothrombocytopenia

Factitious

Asymptomatic; in vitro agglutination of platelets

Repeat CBC using non-EDTA anticoagulant

No treatment indicated

Peripheral blood smear will demonstrate clumping

Thrombotic thrombocytopenic purpura/hemolytic uremic syndrome

Moderate to severe

Most common presentation is nonspecific and includes abdominal pain, nausea/vomiting, and weakness; patients with thrombotic thrombocytopenic purpura may have neurologic abnormalities at presentation

Microangiopathic hemolytic anemia; impaired renal function; neurologic abnormalities; proteinuria; increased LDH, increased bilirubin, and decreased haptoglobin levels

Plasma exchange

10 to 30 percent mortality despite treatment; in children, hemolytic uremic syndrome presents with gastroenteritis (bloody diarrhea) and 60 percent will have thrombocytopenia


ALT = alanine transaminase; AST = aspartate transaminase; CBC = complete blood count; EDTA = ethylenediaminetetraacetic acid; ELISA = enzyme-linked immunosorbent assay; GGT = γ-glutamyltransferase; HELLP = hemolysis, elevated liver enzymes, and low platelet count; ITP = immune thrombocytopenic purpura; IVIG = intravenous immune globulin; LDH = lactate dehydrogenase; MMR = measles, mumps, and rubella.

Information from references 7 through 14.

Table 2.   Common Etiologies of Thrombocytopenia with Clinical Findings and Suggested Treatment

View Table

Table 2.

Common Etiologies of Thrombocytopenia with Clinical Findings and Suggested Treatment

Etiology Severity Clinical presentation Evaluation Treatment Comments

Bone marrow suppression by irradiation, chemotherapy, or neoplasia

Moderate to severe

History of exposure, comorbid preexisting disease, or malignancy

Acute leukemias present with fatigue, weakness, bruising, hepatosplenomegaly

Directed by preexisting diagnosis, specific cancer markers

Abnormal blood smear or bone marrow biopsy

Based on underlying etiology

Usually affects all cell lines

Chronic alcohol abuse

Mild to moderate

Findings range from normal to evidence of cirrhosis or hepatic failure

Positive screening questionnaire, abnormal liver function tests (AST/ALT > 2, GGT), macrocytosis, folate deficiency, hepatic imaging as clinically indicated

Cessation of alcohol use, vitamin and nutritional replacement

Cessation of alcohol use may lead to platelet rebound (> 500 × 103 per μL [500 × 109 per L]) at one to two weeks

Chronic liver disease

Mild to severe

Symptoms are variable based on evidence of cirrhosis, liver dysfunction, gastrointestinal bleeding, ascites, hepatomegaly, and jaundice

Abnormal intrinsic liver function testing, imaging and liver biopsy as clinically indicated

Based on etiology; often supportive

Hypersplenism often is present contributing to thrombocytopenia

Congenital thrombocytopenia

Mild to moderate

Long history of abnormal platelet count or family history of thrombocytopenia

Many disorders associated with giant platelets, neutrophil inclusions, or other congenital anomalies

Varies depending on primary abnormality

Often asymptomatic when there is no bleeding diathesis

Disseminated intravascular coagulation

Severe

Acute illness; bleeding, acute renal failure, hepatic and respiratory dysfunction, and shock are common clinical manifestations

Secondary to other comorbid conditions, such as sepsis, trauma, burns, or malignancy

\

Prolonged coagulation activation, elevated fibrin markers, and accelerated fibrinolysis (low fibrinogen levels)

Supportive treatment with platelet and clotting factor replacement therapy

Mortality rates exceed 20 percent; prognosis is based on treating the underlying disorder

Drug-induced thrombocytopenia

Moderate to severe

Can range from asymptomatic to evidence of clinical bleeding

Detailed history of recent prescription medications, nutritional supplements, and over-the-counter agents

Removal of offending agent

Serial platelet monitoring until normalization

May be initially indistinguishable from ITP

Often resolves within seven to 14 days after agent is discontinued

Gestational thrombocytopenia

Mild

Asymptomatic with platelet counts rarely < 70 × 103 per μL (70 × 109 per L)

Identified during initial prenatal CBC

No associated fetal thrombocytopenia

Spontaneous resolution after delivery

No treatment indicated

Platelet counts approaching 50 ×103 per μL (50 × 109 per L) often are considered ITP and treated with corticosteroids or IVIG

Possible immunologic etiology

May be difficult to distinguish from ITP before delivery

Up to 15 percent of infants with thrombocytopenia are born to women with ITP

Heparin-induced thrombocytopenia

Mild to moderate

Thrombocytopenia or a 50 percent reduction after exposure to heparin or low-molecular-weight heparin

Arterial and venous thrombosis

History of heparin use; erythema or necrosis at site of injection; thrombosis; ELISA test for presence of platelet factor 4 antibodies

Immediate withdrawal of heparin; treatment with nonheparin anticoagulant

Warfarin (Coumadin) monotherapy may induce thrombosis and is contraindicated in the acute setting

Immune thrombocytopenic purpura

Moderate to severe

Often asymptomatic, although symptoms can range from petechiae and easy bruising to severe bleeding diathesis (rare)

Secondary ITP may present in patients with autoimmune disorders, infections (e.g., cytomegalovirus, Epstein-Barr virus, Helicobacter pylori, hepatitis C virus, human immunodeficiency virus, varicella-zoster virus), and lymphoproliferative disorders

Remainder of CBC normal; normal peripheral blood smear; absence of clinically associated conditions

Secondary ITP causes should be investigated as clinically indicated

Corticosteroids, IVIG, rituximab (Rituxan), splenectomy

Treatment not indicated for platelet counts > 50 × 103 per μL unless active bleeding

Secondary ITP also requires treatment of underlying cause

Diagnosis of exclusion

Patients older than 60 years should have bone marrow biopsy to rule out myelodysplastic syndrome or lymphoproliferative disorder

MMR vaccination causes one case of ITP per 40,000 doses

Infections (viral or rickettsial)

Mild to moderate

Viral: prodrome or asymptomatic; known viruses include cytomegalovirus, Epstein- Barr virus, hepatitis B and C viruses, human immunodeficiency virus, parvovirus B19, varicella-zoster virus

Rickettsial: Lyme disease, Rocky Mountain spotted fever, ehrlichiosis; tick-borne illnesses present with fever, headache, malaise, arthralgias, and rash

Viral: diagnosis based on viral etiology; directed antiviral titer testing if available

Rickettsial: ELISA testing may be useful

Viral: based on viral etiology; most self-limited viral infections are supportive

Rickettsial: doxycycline is recommended in symptomatic tick-borne disease

Viral: varicella (live) and influenza A (H1N1) vaccinations have been reported to cause mild transient thrombocytopenia

Rickettsial: ehrlichiosis causes more severe thrombocytopenia than Rocky Mountain spotted fever and Lyme disease

Preeclampsia/HELLP syndrome

Mild to moderate

Elevated blood pressure, visual symptoms, headache, right upper quadrant abdominal pain, influenza-like symptoms

CBC, liver function test, urine protein level, increased uric acid level, increased LDH level, basic metabolic panel

Delivering the fetus; intravenous magnesium sulfate

Recovery usually is within three days of delivery

If persistent beyond the third day after delivery, presume thrombotic thrombocytopenic purpura

Pseudothrombocytopenia

Factitious

Asymptomatic; in vitro agglutination of platelets

Repeat CBC using non-EDTA anticoagulant

No treatment indicated

Peripheral blood smear will demonstrate clumping

Thrombotic thrombocytopenic purpura/hemolytic uremic syndrome

Moderate to severe

Most common presentation is nonspecific and includes abdominal pain, nausea/vomiting, and weakness; patients with thrombotic thrombocytopenic purpura may have neurologic abnormalities at presentation

Microangiopathic hemolytic anemia; impaired renal function; neurologic abnormalities; proteinuria; increased LDH, increased bilirubin, and decreased haptoglobin levels

Plasma exchange

10 to 30 percent mortality despite treatment; in children, hemolytic uremic syndrome presents with gastroenteritis (bloody diarrhea) and 60 percent will have thrombocytopenia


ALT = alanine transaminase; AST = aspartate transaminase; CBC = complete blood count; EDTA = ethylenediaminetetraacetic acid; ELISA = enzyme-linked immunosorbent assay; GGT = γ-glutamyltransferase; HELLP = hemolysis, elevated liver enzymes, and low platelet count; ITP = immune thrombocytopenic purpura; IVIG = intravenous immune globulin; LDH = lactate dehydrogenase; MMR = measles, mumps, and rubella.

Information from references 7 through 14.

Table 3.

Clinical Considerations to Aid in Diagnosis of Thrombocytopenia

Clinical consideration Possible diagnosis

Timing

Acute

Acute infection (primarily viral), acute leukemias, aplastic anemia, chemotherapy or irradiation, drug-induced thrombocytopenia, HELLP syndrome/preeclampsia, heparin-induced thrombocytopenia, ITP, malignancies with marrow infiltration, myelofibrosis, TTP/HUS

Chronic

Chronic alcohol abuse, congenital syndromes, ITP, liver disease, myelodysplastic syndrome

History

Family history

Congenital thrombocytopenia

Liver disease

Chronic alcohol abuse, chronic liver disease

Pregnancy

Gestational thrombocytopenia, HELLP syndrome/preeclampsia

Recent change in medication

Drug-induced thrombocytopenia

Recent hospitalization

Heparin-induced thrombocytopenia

Recent immunization

MMR, varicella, influenza A (H1N1)

Recent transfusion or high-risk behavior

Alloimmune destruction, posttransfusion purpura, viral infection (HCV, HIV)

Recent travel

Dengue fever, malaria, rickettsial diseases

Recent valve replacement surgery

Mechanical destruction

Symptoms

Abdominal pain

HELLP syndrome/preeclampsia, HUS, platelet sequestration

Recent fever

Viral infections (CMV, EBV, HIV, influenza A [H1N1], parvovirus B19), TTP, rickettsial diseases

Weight loss or night sweats

HIV, malignancies (acute leukemias, myelodysplastic syndrome)

Physical examination

Acute rash

Rickettsial diseases, SLE, viral infections

Generalized lymphadenopathy

Viral infections (CMV, EBV, HIV), SLE, myeloproliferative disorders, lymphoproliferative disorders

Hepatomegaly

Chronic liver disease, acute leukemias, viral infections (CMV, EBV, HBV, HCV)

Neurologic

TTP

Splenomegaly*

Autoimmune (SLE, sarcoidosis), hypersplenism, viral infections


CMV = cytomegalovirus; EBV = Epstein-Barr virus; HBV = hepatitis B virus; HCV = hepatitis C virus; HELLP = hemolysis, elevated liver enzymes, and low platelet count; HIV = human immunodeficiency virus; HUS = hemolytic uremic syndrome; ITP = immune thrombocytopenic purpura; MMR = measles, mumps, and rubella; SLE = systemic lupus erythematosus; TTP = thrombotic thrombocytopenic purpura.

*—Ultrasonography may be useful in patients who are obese.

Table 3.   Clinical Considerations to Aid in Diagnosis of Thrombocytopenia

View Table

Table 3.

Clinical Considerations to Aid in Diagnosis of Thrombocytopenia

Clinical consideration Possible diagnosis

Timing

Acute

Acute infection (primarily viral), acute leukemias, aplastic anemia, chemotherapy or irradiation, drug-induced thrombocytopenia, HELLP syndrome/preeclampsia, heparin-induced thrombocytopenia, ITP, malignancies with marrow infiltration, myelofibrosis, TTP/HUS

Chronic

Chronic alcohol abuse, congenital syndromes, ITP, liver disease, myelodysplastic syndrome

History

Family history

Congenital thrombocytopenia

Liver disease

Chronic alcohol abuse, chronic liver disease

Pregnancy

Gestational thrombocytopenia, HELLP syndrome/preeclampsia

Recent change in medication

Drug-induced thrombocytopenia

Recent hospitalization

Heparin-induced thrombocytopenia

Recent immunization

MMR, varicella, influenza A (H1N1)

Recent transfusion or high-risk behavior

Alloimmune destruction, posttransfusion purpura, viral infection (HCV, HIV)

Recent travel

Dengue fever, malaria, rickettsial diseases

Recent valve replacement surgery

Mechanical destruction

Symptoms

Abdominal pain

HELLP syndrome/preeclampsia, HUS, platelet sequestration

Recent fever

Viral infections (CMV, EBV, HIV, influenza A [H1N1], parvovirus B19), TTP, rickettsial diseases

Weight loss or night sweats

HIV, malignancies (acute leukemias, myelodysplastic syndrome)

Physical examination

Acute rash

Rickettsial diseases, SLE, viral infections

Generalized lymphadenopathy

Viral infections (CMV, EBV, HIV), SLE, myeloproliferative disorders, lymphoproliferative disorders

Hepatomegaly

Chronic liver disease, acute leukemias, viral infections (CMV, EBV, HBV, HCV)

Neurologic

TTP

Splenomegaly*

Autoimmune (SLE, sarcoidosis), hypersplenism, viral infections


CMV = cytomegalovirus; EBV = Epstein-Barr virus; HBV = hepatitis B virus; HCV = hepatitis C virus; HELLP = hemolysis, elevated liver enzymes, and low platelet count; HIV = human immunodeficiency virus; HUS = hemolytic uremic syndrome; ITP = immune thrombocytopenic purpura; MMR = measles, mumps, and rubella; SLE = systemic lupus erythematosus; TTP = thrombotic thrombocytopenic purpura.

*—Ultrasonography may be useful in patients who are obese.

The physical examination should include the eyes (e.g., hemorrhage is suggestive of central nervous system bleeding), abdomen (e.g., splenomegaly, hepatomegaly), lymph nodes (e.g., lymphadenopathy), skin (e.g., petechiae, purpura, bruising), and neurologic system. Bleeding (e.g., epistaxis, mucosal, gastrointestinal, genitourinary) also should be assessed. Thrombocytopenia can be classified as emergent (usually requires inpatient management) or nonemergent (outpatient management). Some syndromes may fall in either category based on the severity of thrombocytopenia.

A peripheral blood smear can provide diagnostic information on a variety of white blood cell disorders, hemolytic anemias, and thrombocytopenia.15  A blood smear should be obtained during the initial evaluation. Table 4 lists common findings on peripheral blood smear and their associated diagnoses.

Table 4.

Common Peripheral Blood Smear Findings and Possible Diagnoses

Smear findings Possible diagnosis Comments

Atypical lymphocytosis

Viral infection (e.g., Epstein-Barr virus, cytomegalovirus)

Abundant cytoplasm

Basophilic stippling

Thalassemia, chronic alcohol use, lead or metal poisoning

Ribosomal precipitate (appears as blue granules) throughout the cytoplasm of the red blood cell

Cryoglobulin

Cryoglobulinemia, mycoplasma pneumonia, multiple myeloma, some autoimmune disorders

Proteins that precipitate when blood is below normal body temperature

Giant platelets

Congenital thrombocytopenias, immune thrombocytopenic purpura

Caused by increased platelet turnover or release of immature forms into the circulation

Megakaryocyte fragments

Myelofibrosis

Presence of large platelets

Nucleated red blood cells

Severe hemolysis, myelofibrosis

Immature red blood cells secondary to accelerated erythropoiesis

Oval macrocytosis

Vitamin B12 and folate deficiencies

Suggests impaired bone marrow synthesis

Platelet agglutination

Pseudothrombocytopenia

Clumping of platelets in patients with EDTA-activated antiplatelet antibodies

Platelet hypogranularity

Myelodysplastic syndrome, myelofibrosis

Suggests impaired bone marrow synthesis

Round macrocytosis

Myelodysplastic syndrome, myelofibrosis, chronic liver disease

Suggests impaired bone marrow synthesis

Schistocytosis

Thrombotic thrombocytopenic purpura, hemolytic uremic syndrome, disseminated intravascular coagulation, defective prosthetic heart valve

Fragmented erythrocytes

Target cells

Chronic liver disease, hemoglobinopathies

Excess hemoglobin in the center of the red blood cell


EDTA = ethylenediaminetetraacetic acid.

Table 4.   Common Peripheral Blood Smear Findings and Possible Diagnoses

View Table

Table 4.

Common Peripheral Blood Smear Findings and Possible Diagnoses

Smear findings Possible diagnosis Comments

Atypical lymphocytosis

Viral infection (e.g., Epstein-Barr virus, cytomegalovirus)

Abundant cytoplasm

Basophilic stippling

Thalassemia, chronic alcohol use, lead or metal poisoning

Ribosomal precipitate (appears as blue granules) throughout the cytoplasm of the red blood cell

Cryoglobulin

Cryoglobulinemia, mycoplasma pneumonia, multiple myeloma, some autoimmune disorders

Proteins that precipitate when blood is below normal body temperature

Giant platelets

Congenital thrombocytopenias, immune thrombocytopenic purpura

Caused by increased platelet turnover or release of immature forms into the circulation

Megakaryocyte fragments

Myelofibrosis

Presence of large platelets

Nucleated red blood cells

Severe hemolysis, myelofibrosis

Immature red blood cells secondary to accelerated erythropoiesis

Oval macrocytosis

Vitamin B12 and folate deficiencies

Suggests impaired bone marrow synthesis

Platelet agglutination

Pseudothrombocytopenia

Clumping of platelets in patients with EDTA-activated antiplatelet antibodies

Platelet hypogranularity

Myelodysplastic syndrome, myelofibrosis

Suggests impaired bone marrow synthesis

Round macrocytosis

Myelodysplastic syndrome, myelofibrosis, chronic liver disease

Suggests impaired bone marrow synthesis

Schistocytosis

Thrombotic thrombocytopenic purpura, hemolytic uremic syndrome, disseminated intravascular coagulation, defective prosthetic heart valve

Fragmented erythrocytes

Target cells

Chronic liver disease, hemoglobinopathies

Excess hemoglobin in the center of the red blood cell


EDTA = ethylenediaminetetraacetic acid.

Long-term Outcomes of Incidental Thrombocytopenia

The findings of isolated thrombocytopenia in an outpatient setting have prognostic implications. A prospective study evaluated the long-term outcomes of patients with incidental thrombocytopenia. The study followed 217 persons with platelet counts from 100 to 150 × 103 per μL (100 to 150 × 109 per L) over a 10-year period. In 64 percent of patients, platelet counts normalized or remained stable. The probability of developing immune thrombocytopenic purpura or an autoimmune disorder was approximately 7 and 12 percent, respectively. Four cases of myelodysplastic syndrome were diagnosed (2 percent), all of which were in older patients.16

Factitious Thrombocytopenia

Pseudothrombocytopenia is secondary to platelet clumping and has no clinical significance. It occurs in one in 1,000 persons in the general population, and can be confirmed by a peripheral blood smear.3 Causes include use of abciximab (Reopro) or ethylenediaminetetraacetic acid–dependent agglutinins.17,18 The platelet count should be repeated by collecting blood in a tube with a non-ethylenediaminetetraacetic acid anticoagulant, such as heparin or sodium citrate. If the complete blood count still shows thrombocytopenia, other causes should be investigated.

Emergent Thrombocytopenia

IMMUNE (IDIOPATHIC) THROMBOCYTOPENIC PURPURA

Immune thrombocytopenic purpura is an acquired immune-mediated disorder characterized by isolated thrombocytopenia and the absence of other conditions or agents known to induce thrombocytopenia. The incidence is 100 cases per 1 million persons annually, and approximately 50 percent of cases occur in children.2 Immune thrombocytopenic purpura in children often resolves spontaneously but tends to be more insidious and chronic in adults. The risk of bleeding correlates to the severity of thrombocytopenia. Patients may present without symptoms, with minimal bleeding, or with serious hemorrhage (e.g., mucosal, intracranial, gastrointestinal, genitourinary). Older patients, patients on antiplatelet therapy, and patients with comorbid conditions may have more severe bleeding manifestations.19

Secondary immune thrombocytopenic purpura is associated with other underlying conditions, such as autoimmune disorders (e.g., systemic lupus erythematosus, antiphospholipid syndrome, Graves disease, sarcoidosis), lymphoproliferative disorders, and infections (e.g., human immunodeficiency virus, Epstein-Barr virus, cytomegalovirus, varicella-zoster virus, hepatitis C virus, Helicobacter pylori). Testing to rule out other causes should be performed as clinically indicated. Forty percent of patients with immune thrombocytopenic purpura test positive for antinuclear or antiphospholipid antibodies without having an underlying autoimmune syndrome.20 Treatment is generally restricted to those with severe thrombocytopenia and is rarely indicated when platelet counts are greater than 50 × 103 per μL unless there is evidence of active bleeding. Corticosteroids are considered first-line treatment and increase platelet counts usually within one week of initiation.2,21 Intravenous immune globulin and rituximab (Rituxan) also have been used for initial treatment of immune thrombocytopenic purpura. Second-line treatment includes thrombopoietin-receptor agonists and splenectomy. Any patient older than 60 years presenting with isolated thrombocytopenia should be evaluated for myelodysplastic syndrome and lympho-proliferative disorders.2,21

HEPARIN-INDUCED THROMBOCYTOPENIA

Heparin-induced thrombocytopenia should be suspected in patients recently treated with heparin. Platelet counts decline within five to 10 days in patients with no previous exposure to heparin and may decline precipitously (within hours) in patients with recent heparin exposure. This life-threatening disorder is characterized by the presence of platelet-activating antibodies recognizing multimolecular complexes bound to unfractionated heparin or low-molecular-weight heparin. Patients with heparin-induced thrombocytopenia present with mild thrombocytopenia or a 50 percent decrease in platelet count from baseline.22 The incidence is higher among surgical patients than medical patients. Thrombosis complications (termed heparin-induced thrombocytopenia with thrombosis) develop in 20 to 50 percent of patients and may affect arterial and venous systems, even after heparin is discontinued.23

Characteristic features are erythematous or necrotizing skin reactions at the site of injection or severe manifestations, such as deep venous thrombosis, pulmonary emboli, stroke, or myocardial infarction. The most widely available diagnostic test is an enzyme-linked immunosorbent assay with platelet factor 4/anion complex as the antigen. This test has a high sensitivity (greater than 97 percent) but a lower specificity (74 to 86 percent) because of the presence of platelet factor 4 antibodies in patients without heparin-induced thrombocytopenia.22,24 If the clinical diagnosis is suspected or confirmed by laboratory analysis, heparin should be stopped immediately and treatment should be changed to a nonheparin anticoagulant. One study showed that patients who developed heparin-induced thrombocytopenia had a 20 percent in-hospital mortality rate, regardless of thrombosis development.25

THROMBOTIC THROMBOCYTOPENIC PURPURA

Patients presenting with thrombocytopenia and microangiopathic hemolytic anemia should be admitted to the hospital with a presumptive diagnosis of thrombotic thrombocytopenic purpura. Renal manifestations, neurologic changes, and fever also may be present. Severity is reflected by the extent of microvascular aggregation of platelets resulting in ischemia and necrosis of tissue cells. The incidence of thrombotic thrombocytopenic purpura is four to 11 patients per 1 million annually in the United States.7 The condition often is caused by the absence or deficiency of a disintegrin and metalloproteinase with thrombospondin type 1 motif, member 13.7 It is fatal without treatment; prompt initiation of plasma exchange is critical. Thrombotic thrombocytopenic purpura occurs primarily in adults. Hemolytic uremic syndrome is thrombotic thrombocytopenic purpura found in children presenting with acute renal failure, bloody diarrhea, and/or abdominal pain. Shiga toxin-producing Escherichia coli is the most common causative organism in hemolytic uremic syndrome.26

PREECLAMPSIA AND HELLP SYNDROME

Pregnant patients beyond 20 weeks' gestation with thrombocytopenia or signs and symptoms such as headache, visual disturbances, right upper quadrant abdominal pain, or elevated blood pressure should be evaluated for preeclampsia and HELLP syndrome. Laboratory abnormalities may include anemia, elevated liver enzymes, elevated lactate dehydrogenase, and proteinuria.27 Treatment is intravenous magnesium sulfate and active management to deliver the fetus.28 Pregnant patients also can present with other causes of thrombocytopenia, including disseminated intravascular coagulation (as seen with sepsis and placenta abruptio) and thrombotic thrombocytopenic purpura, which can mimic HELLP syndrome.

OTHER CAUSES

Aplastic anemia, chemotherapy, irradiation, acute leukemias, and myelodysplastic disorders may result in severe or symptomatic thrombocytopenia. Paroxysmal nocturnal hemoglobinuria is associated with hemolysis, renal disease, and thrombosis complications. Hospitalized patients with comorbid conditions, such as sepsis, trauma, burns, or malignancy, can develop disseminated intravascular coagulation with resultant thrombocytopenia.

Nonemergent Thrombocytopenia

DRUG-INDUCED THROMBOCYTOPENIA

One of the most common types of thrombocytopenia in the outpatient setting is drug-induced thrombocytopenia. An epidemiologic study from Europe and the United States showed an annual incidence of 10 cases per 1 million persons, but numbers could be higher in older persons and in hospitalized patients.29 Drug-induced thrombocytopenia should be suspected in all patients presenting with an acute drop in platelet count. Most patients with drug-induced thrombocytopenia have moderate to severe thrombocytopenia reaching a nadir platelet count of 20 × 103 per μL.8 Physicians should ask specific questions about the use of any medications, including nutritional supplements and over-the-counter remedies. Quinine is a common cause of drug-induced thrombocytopenia and often is missed in the patient history.

Table 5 lists common medications that may cause thrombocytopenia.8 A comprehensive list of all case reports describing drug-induced thrombocytopenia is available at http://www.ouhsc.edu/platelets. Drug-induced thrombocytopenia typically occurs within five to seven days of exposure to the causative agent and usually resolves within seven to 14 days after discontinuation.30 If drug-induced thrombocytopenia is suspected, the causative medication should be discontinued and the patient's platelet count should be repeated in one week.

Table 5.

Medications/Substances Commonly Associated with Drug-Induced Thrombocytopenia

Medication/substance Drug class Proposed mechanism of action

Abciximab (Reopro)

Glycoprotein IIb/IIIa inhibitor

Drug-specific antibody

Alcohol

Ethanol

Suppression of megakaryocyte production

Carbamazepine (Tegretol)

Anticonvulsant

Unknown

Cephalosporins

Antibiotic

Hapten-dependent

Cimetidine (Tagamet)

Histamine H2 blocker

Unknown

Eptifibatide (Integrilin)

Glycoprotein IIb/IIIa inhibitor

Drug-specific antibody

Gold salts

Antirheumatic

Autoantibody

Heparin

Anticoagulant

Platelet factor 4/heparin antibody

Hydrochlorothiazide

Antihypertensive

Suppression of megakaryocyte production

Interferon

Antiviral

Drug-specific antibody

Measles, mumps, and rubella vaccine

Vaccine

Vaccine-specific antibody

Phenytoin (Dilantin)

Anticonvulsant

Unknown

Procainamide

Antiarrhythmic

Autoantibody

Quinidine/quinine

Cinchona alkaloid

Drug-glycoprotein complex

Rifampin

Antibiotic

Autoantibody

Sulfasalazine (Azulfidine)

Anti-inflammatory

Drug-specific antibody

Trimethoprim/sulfamethoxazole (Bactrim, Septra)

Antibiotic

Drug-glycoprotein complex

Vancomycin

Antibiotic

Drug-specific antibody


Adapted with permission from Kenney B, Stack G. Drug-induced thrombocytopenia. Arch Pathol Lab Med. 2009;133(2):314. Copyright 2009. College of American Pathologists.

Table 5.   Medications/Substances Commonly Associated with Drug-Induced Thrombocytopenia

View Table

Table 5.

Medications/Substances Commonly Associated with Drug-Induced Thrombocytopenia

Medication/substance Drug class Proposed mechanism of action

Abciximab (Reopro)

Glycoprotein IIb/IIIa inhibitor

Drug-specific antibody

Alcohol

Ethanol

Suppression of megakaryocyte production

Carbamazepine (Tegretol)

Anticonvulsant

Unknown

Cephalosporins

Antibiotic

Hapten-dependent

Cimetidine (Tagamet)

Histamine H2 blocker

Unknown

Eptifibatide (Integrilin)

Glycoprotein IIb/IIIa inhibitor

Drug-specific antibody

Gold salts

Antirheumatic

Autoantibody

Heparin

Anticoagulant

Platelet factor 4/heparin antibody

Hydrochlorothiazide

Antihypertensive

Suppression of megakaryocyte production

Interferon

Antiviral

Drug-specific antibody

Measles, mumps, and rubella vaccine

Vaccine

Vaccine-specific antibody

Phenytoin (Dilantin)

Anticonvulsant

Unknown

Procainamide

Antiarrhythmic

Autoantibody

Quinidine/quinine

Cinchona alkaloid

Drug-glycoprotein complex

Rifampin

Antibiotic

Autoantibody

Sulfasalazine (Azulfidine)

Anti-inflammatory

Drug-specific antibody

Trimethoprim/sulfamethoxazole (Bactrim, Septra)

Antibiotic

Drug-glycoprotein complex

Vancomycin

Antibiotic

Drug-specific antibody


Adapted with permission from Kenney B, Stack G. Drug-induced thrombocytopenia. Arch Pathol Lab Med. 2009;133(2):314. Copyright 2009. College of American Pathologists.

INFECTIONS

Infections may cause thrombocytopenia by direct bone marrow suppression or increased peripheral platelet consumption. Common viruses include hepatitis B and C, human immunodeficiency virus, Epstein-Barr, cytomegalovirus, parvovirus B19, varicellazoster, rubella, and mumps. Recent studies found thrombocytopenia in 14 percent of hospitalized patients with influenza A (H1N1) virus.31 Platelet counts usually recover in patients with a self-limited viral infection. If the patient has a recent travel history, especially to South America or Mexico, dengue fever and malaria should be considered. Other travel-associated infections, such as typhoid fever , can cause thrombocytopenia.32 Ehrlichiosis, Rocky Mountain spotted fever, and Lyme disease are common tick-borne illnesses that can cause transient thrombocytopenia.33

LIVER DISEASE

Chronic liver disease usually causes persistent thrombocytopenia, and manifests as cirrhosis, fibrosis, and portal hypertension. The most common cause is chronic alcohol abuse; however, other etiologies include infectious hepatitis, drug-induced liver disease, nonalcoholic liver disease, and metabolic disorders. Patients who consume excessive amounts of alcohol can present with varying degrees of liver impairment ranging from asymptomatic fatty liver to end-stage liver disease. Thrombocytopenia results from direct toxic marrow suppression and splenic sequestration. Folic acid deficiency (related to malnutrition) often coexists with alcohol abuse. Abstinence and nutritional replacement often lead to platelet normalization in three to four weeks in the absence of chronic liver disease.34

GESTATIONAL THROMBOCYTOPENIA

Gestational thrombocytopenia is the most common diagnosis of thrombocytopenia in pregnancy, occurring in 8 percent of pregnancies.9,10 Its etiology is thought to be hemodilution and accelerated platelet clearance. Gestational thrombocytopenia is characterized by mild thrombocytopenia, no history of thrombocytopenia, no association of fetal thrombocytopenia, and spontaneous resolution after delivery.35,36 Gestational thrombocytopenia is a benign clinical condition not associated with maternal or neonatal morbidity or mortality.

Recommendations for the initial evaluation of thrombocytopenia in pregnancy include a complete blood count and peripheral blood smear.10 Additional studies are determined on the basis of history and physical examination. Pregnant patients with platelet counts greater than 115 × 103 per μL (115 × 109 per L) and no evidence of preeclampsia or HELLP syndrome do not require further evaluation.9,37

Mild immune thrombocytopenic purpura and gestational thrombocytopenia often are indistinguishable and cannot be differentiated on the basis of antiplatelet antibody screening; however, 12 to 15 percent of neonates delivered to women with immune thrombocytopenic purpura will develop platelet counts of less than 50 × 103 per μL.38 The platelet count in infants should be monitored when immune thrombocytopenic purpura is suspected in the mother.

Management

A suggested algorithm for the management of thrombocytopenia is shown in Figure 1.4 Symptomatic patients require immediate evaluation. Patients with incidental thrombocytopenia (i.e., platelet counts of 50 to 150 × 103 per μL) who are asymptomatic should have a platelet count repeated in one to four weeks depending on the severity of thrombocytopenia.16 Reassessment should be performed immediately if patients become symptomatic during the surveillance period. Additional laboratory evaluation should be performed as clinically indicated, and a trial of discontinuing agents known to decrease platelet counts is recommended. Patients with chronic alcohol abuse or known nutritional deficiencies with stable thrombocytopenia can be treated by a primary care physician. Rickettsial diseases and most viral infections causing transient thrombocytopenia also can be managed by a primary care physician. Patients with unexplained severe thrombocytopenia, decreasing platelet counts, additional hematologic abnormalities, or associated bleeding complications should be referred to a hematologist.

Management of Thrombocytopenia

Figure 1

Algorithm for the management of thrombocytopenia. (DIC = disseminated intravascular coagulation; EDTA = ethylenediaminetetraacetic acid; HELLP = hemolysis, elevated liver enzymes, and low platelet count; HUS = hemolytic uremic syndrome; ITP = immune thrombocytopenic purpura; TTP = thrombotic thrombocytopenic purpura.)

Information from reference 4.

View Large

Management of Thrombocytopenia


Figure 1

Algorithm for the management of thrombocytopenia. (DIC = disseminated intravascular coagulation; EDTA = ethylenediaminetetraacetic acid; HELLP = hemolysis, elevated liver enzymes, and low platelet count; HUS = hemolytic uremic syndrome; ITP = immune thrombocytopenic purpura; TTP = thrombotic thrombocytopenic purpura.)

Information from reference 4.

Management of Thrombocytopenia


Figure 1

Algorithm for the management of thrombocytopenia. (DIC = disseminated intravascular coagulation; EDTA = ethylenediaminetetraacetic acid; HELLP = hemolysis, elevated liver enzymes, and low platelet count; HUS = hemolytic uremic syndrome; ITP = immune thrombocytopenic purpura; TTP = thrombotic thrombocytopenic purpura.)

Information from reference 4.

Activity Participation and Invasive Procedures

General recommendations for activity participation have been based on historical data from patients with chronic severe thrombocytopenia.39,40 A platelet count greater than 50 × 103 per μL is adequate for hemostasis and is unlikely to be clinically recognized. Patients with a platelet count greater than this level can engage in most activities, but should use caution if participating in contact sports.16,40 Patients with platelet counts less than 10 × 103 per μL should be restricted from contact sports and other potentially traumatic activities. In one study, 42 percent of patients with platelet counts less than 10 × 103 per μL had spontaneous bleeding requiring intervention (e.g., nasal packing) compared with 6 percent of patients with counts between 10 and 30 × 103 per μL.39

Most surgical and invasive procedures can be performed safely in patients with platelet counts greater than 50 × 103 per μL. Other procedures, such as bone marrow biopsy, bronchoscopy, and endoscopy, can be completed safely in patients with platelet counts greater than 20 × 103 per μL, provided that no other bleeding abnormalities are noted.41,42 The American College of Obstetricians and Gynecologists recommendations state that epidural anesthesia in pregnancy is safe in patients with platelet counts between 50 and 100 × 103 per μL.10

Data Sources: The authors searched OvidSP, UpToDate, American Academy of Family Physicians, American College of Obstetricians and Gynecologists, American Society of Clinical Oncology Practice Guidelines, Hematology/Oncology Clinics or North America, Harrison's Principles of Internal Medicine (17th edition), Agency of Healthcare Research and Quality Evidence Reports, National Guidelines Clearinghouse, Cochrane Database of Systematic Reviews, and the Centre for Reviews and Dissemination. Key words included: thrombocytopenia, review, treatment, idiopathic (immune) thrombocytopenic purpura, thrombocytopenia in pregnancy, thrombotic thrombocytopenic purpura, heparin-induced thrombocytopenia, hemolytic uremic syndrome, preeclampsia, HELLP syndrome, gestational thrombocytopenia, pseudothrombocytopenia, myelodysplastic syndrome, microangiopathic hemoglobinopathies, drug-induced thrombocytopenia, platelet transfusion, inherited thrombocytopenias, antiphospholipid antibodies, and viral infections. Information published between 1996 and June 2010 was included. Original search dates: April 5 and June 16, 2010. Final search date: November 23, 2011.

The Authors

ROBERT L. GAUER, MD, is a faculty physician at Womack Army Medical Center Family Medicine Residency at Fort Bragg, N.C., where he serves as the research and scholarship advisor. He also is an assistant professor of family medicine at the Uniformed Services University of the Health Sciences in Bethesda, Md.

MICHAEL M. BRAUN, DO, is the 3rd Battalion Surgeon for the 1st Special Forces Group based at Fort Lewis, Wash.

Address correspondence to Robert L. Gauer, MD, Womack Army Medical Center, Bldg. 4–2817, Riley Rd., Fort Bragg, NC 28310 (e-mail: Robert.gauer@us.army.mil). Reprints are not available from the authors.

Author disclosure: No relevant financial affiliations to disclose.

The authors thank Penelope Harris, MD, for her assistance with the manuscript.

The opinions and assertions contained herein are the private views of the authors and are not to be construed as official or as reflecting the views of the U.S. Army Medical Department or the U.S. Army at large.

REFERENCES

1. Buckley MF, James JW, Brown DE, et al. A novel approach to the assessment of variations in the human platelet count. Thromb Haemost. 2000;83(3):480–484.

2. Cines DB, Blanchette VS. Immune thrombocytopenic purpura. N Engl J Med. 2002;346(13):995–1008.

3. Veneri D, Franchini M, Randon F, Nichele I, Pizzolo G, Ambrosetti A. Thrombocytopenias: a clinical point of view. Blood Transfus. 2009;7(2):75–85.

4. Finnish Medical Society Duodecim Thrombocytopenia In: EBM Guidelines Evidence-Based Medicine. Helsinki, Finland: Wiley Interscience. John Wiley & Sons. April 27, 2007. http://www.guideline.gov/content.aspx?id=11048. Accessed November 25, 2011.

5. Landaw SA, George JN. Approach to the adult patient with thrombocytopenia [subscription required]. UpToDate. http://www.uptodate.com/contents/approach-to-the-adult-patient-with-thrombocytopenia. Accessed November 28, 2011

6. Balduini CL, Cattaneo M, Fabris F, et al. Inherited thrombocytopenias: a proposed diagnostic algorithm from the Italian Gruppo di Studio delle Piastrine. Haematologica. 2003;88(5):582–592.

7. George JN. Clinical practice. Thombotic thrombocytopenic purpura. N Engl J Med. 2006;354(18):1927–1935.

8. Kenney B, Stack G. Drug-induced thrombocytopenia. Arch Pathol Lab Med. 2009;133(2):309–314.

9. Boehlen F, Hohlfeld P, Extermann P, et al. Platelet count at term pregnancy: a reappraisal of the threshold. Obstet Gynecol. 2000;95(1):29–33.

10. ACOG practice bulletin: Thrombocytopenia in pregnancy. Number 6, September 1999. Clinical management guidelines for obstetrician-gynecologists. American College of Obstetricians and Gynecologists. Int J Gynaecol Obstet. 1999;67(2):117–128.

11. France EK, Glanz J, Xu S, et al.; Vaccine Safety Datalink Team. Risk of immune thrombocytopenic purpura after measles-mumps-rubella immunization in children. Pediatrics. 2008;121(3):e687–e692.

12. Bratton RL, Corey R. Tick-borne disease. Am Fam Physician. 2005;71(12):2323–2330.

13. Levi M, Toh CH, Thachil J, Watson HG. Guidelines for the diagnosis and management of disseminated intravascular coagulation. British Committee for Standards in Haematology. Br J Haematol. 2009;145(1):24–33.

14. Boyce TG, Swerdlow DL, Griffin PM. Escherichia coli O157:H7 and the hemolyticuremic syndrome. N Engl J Med. 1995;333(6):364–368.

15. Bain BJ. Diagnosis from the blood smear. N Engl J Med. 2005;353(5):498–507.

16. Stasi R, Amadori S, Osborn J, Newland AC, Provan D. Long-term outcome of otherwise healthy individuals with incidentally discovered borderline thrombocytopenia. PLoS Med. 2006;3(3):e24.

17. Vicari A, Banfi G, Bonini PA. EDTA-dependent pseudothrombocytopaenia: a 12-month epidemiological study. Scand J Clin Lab Invest. 1988;48(6):537–542.

18. Sane DC, Damaraju LV, Topol EJ, et al. Occurrence and clinical significance of pseudothrombocytopenia during abciximab therapy. J Am Coll Cardiol. 2000;36(1):75–83.

19. Cortelazzo S, Finazzi G, Buelli M, Molteni A, Viero P, Barbui T. High risk of severe bleeding in aged patients with chronic idiopathic thrombocytopenia purpura. Blood. 1991;77(1):31–33.

20. Diz-Küçükkaya R, et al. Antiphospholipid antibodies and antiphospho-lipid syndrome in patients presenting with immune thrombocytopenic purpura: a prospective cohort study. Blood. 2001;98(6):1760–1764.

21. Provan D, Stasi R, Newland AC, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2010;115(2):168–186.

22. Arepally GM, Ortel TL. Clinical practice. Heparin-induced thrombocytopenia. N Engl J Med. 2006;355(8):809–817.

23. Greinacher A, Farner B, Kroll H, Kohlmann T, Warkentin TE, Eichler P. Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosis. A retrospective analysis of 408 patients. Thromb Haemost. 2005;94(1):132–135.

24. Warkentin TE, Sheppard JA, Moore JC, Moore KM, Sigouin CS, Kelton JG. Laboratory testing for the antibodies that cause heparin-induced thrombocytopenia: how much class do we need? J Lab Clin Med. 2005;146(6):341–346.

25. Baroletti S, Piovella C, Fanikos J, Labreche M, Lin J, Goldhaber SZ. Heparin-induced thrombocytopenia (HIT): clinical and economic outcomes. Thromb Haemost. 2008;100(6):1130–1135.

26. Moake JL. Thrombotic microangiopathies. N Engl J Med. 2002;347(8):589–600.

27. ACOG Committee on Practice Bulletins—Obstetrics. ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002. Obstet Gynecol. 2002;99(1):159–167.

28. Sibai BM. Diagnosis, controversies, and management of the syndrome of hemolysis, elevated liver enzymes, and low platelet count. Obstet Gynecol. 2004;103(5 pt 1):981–991.

29. van den Bemt PM, Meyboom RH, Egberts AC. Drug-induced immune thrombocytopenia. Drug Saf. 2004;27(15):1243–1252.

30. Aster RH, Bougie DW. Drug-induced immune thrombocytopenia. N Engl J Med. 2007;357(6):580–587.

31. Jain S, Kamimoto L, Bramley AM, et al.; 2009 Pandemic Influenza A (H1N1) Virus Hospitalizations Investigation Team. Hospitalized patients with 2009 H1N1 influenza in the United States, April–June 2009. N Engl J Med. 2009;361(20):1935–1944.

32. Ryan ET, Wilson ME, Kain KC. Illness after international travel. N Engl J Med. 2002;347(7):505–516.

33. Chapman AS, Bakken JS, Folk SM, et al.; Tickborne Rickettsial Diseases Working Group; CDC. Diagnosis and management of tickborne rickettsial diseases: Rocky Mountain spotted fever, ehrlichioses, and anaplasmosis—United States: a practical guide for physicians and other health-care and public health professionals. MMWR Recomm Rep. 2006;55(RR-4):1–27.

34. Girard DE, Kumar KL, McAfee JH. Hematologic effects of acute and chronic alcohol abuse. Hematol Oncol Clin North Am. 1987;1(2):321–334.

35. Burrows RF, Kelton JG. Fetal thrombocytopenia and its relation to maternal thrombocytopenia. N Engl J Med. 1993;329(20):1463–1466.

36. Burrows RF, Kelton JG. Low fetal risks in pregnancies associated with idiopathic thrombocytopenic purpura. Am J Obstet Gynecol. 1990;163(4 pt 1):1147–1150.

37. Ruggeri M, Schiavotto C, Castaman G, Tosetto A, Rodeghiero F. Gestational thrombocytopenia: a prospective study. Haematologica. 1997;82(3):341–342.

38. Webert KE, Mittal R, Sigouin C, Heddle NM, Kelton JG. A retrospective 11-year analysis of obstetric patients with idiopathic thrombocytopenic purpura. Blood. 2003;102(13):4306–4311.

39. Lacey JV, Penner JA. Management of idiopathic thrombocytopenic purpura in the adult. Semin Thromb Hemost. 1977;3(3):160–174.

40. George JN. Evaluation and management of thrombocytopenia by primary care physicians [subscription required]. UpToDate. http://www.uptodate.com/contents/evaluation-and-management-of-thrombocytopenia-by-primary-care-physicians. Accessed October 18, 2011.

41. Schiffer CA, Anderson KC, Bennett CL, et al. Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol. 2001;19(5):1519–1538.

42. Slichter SJ. Evidence-based platelet transfusion guidelines. Hemotology Am Soc Hematol Educ Program. 2007:172–178.


Copyright © 2012 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact afpserv@aafp.org for copyright questions and/or permission requests.

Want to use this article elsewhere? Get Permissions


Article Tools

  • Download PDF
  • Print page
  • Share this page
  • AFP CME Quiz

Information From Industry

More in Pubmed

Navigate this Article